The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab

ConclusionsOverall, treatment with ravulizumab in pediatric patients with aHUS who were previously treated with eculizumab resulted in stable kidney and hematologic parameters, with no unexpected safety concerns when administered every 4 –8 weeks.Trial registrationTrial identifiers:Trial ID: ALXN1210-aHUS-312Clinicaltrials.gov: NCT03131219EudraCT number: 2016-002499-29Graphical abstract
Source: Pediatric Nephrology - Category: Urology & Nephrology Source Type: research